On February 27, 2026, the European Medicines Agency (EMA) recommended authorization for mCombriax®, the first combined vaccine designed to protect against both COVID-19 and seasonal influenza in individuals aged 50 years and older. This milestone represents a significant advancement in preventive healthcare, offering the potential for a single annual injection to address two major respiratory illnesses that disproportionately affect older adults.
The recommendation comes after extensive evaluation of clinical data demonstrating mCombriax’s safety and efficacy. According to the EMA, the vaccine utilizes mRNA technology to target specific strains of SARS-CoV-2 and influenza viruses selected based on global surveillance recommendations for the 2023/2024 season. The agency emphasized that the combined approach could simplify vaccination campaigns and improve compliance, particularly among populations at higher risk of severe outcomes from these infections.
Moderna, the developer of mCombriax, stated that the vaccine is intended for annual administration ahead of the typical respiratory virus season. The EMA’s recommendation applies to the European Union, with final authorization expected to follow from the European Commission. If approved, mCombriax would become available for apply in member states starting in late 2026, aligning with the timing of seasonal influenza vaccination programs.
Public health experts note that combining protection against both viruses in one shot could reduce the logistical burden on healthcare systems and increase vaccination rates, especially among older adults who may face challenges accessing multiple separate injections. The development reflects ongoing efforts to innovate vaccine delivery in response to the evolving threat posed by respiratory pathogens.
As of the EMA’s announcement, no serious safety concerns were identified during clinical trials. Common side effects reported were consistent with those seen in standalone mRNA vaccines, including temporary soreness at the injection site, fatigue, headache, and muscle pain. The agency will continue to monitor the vaccine’s performance through post-authorization safety studies once it becomes widely available.
The recommendation marks the first time a combined COVID-19 and influenza vaccine has received a positive opinion from a major regulatory authority. Even as similar approaches are under investigation by other pharmaceutical companies, mCombriax is currently the furthest along in the regulatory process for this specific indication.
Health authorities across Europe are expected to review the EMA’s guidance as they prepare for the 2026/2027 respiratory virus season. National immunization technical advisory groups may issue country-specific recommendations based on local epidemiology and vaccine availability.
For individuals considering vaccination, healthcare providers advise consulting with a doctor to determine the most appropriate timing and type of protection based on personal health status, risk factors, and current public health guidance. Official updates on vaccine availability and administration guidelines will be issued by national health agencies and the EMA as the authorization process progresses.
The next key step in the process is the European Commission’s formal decision on granting EU-wide marketing authorization for mCombriax, which typically follows within a few weeks of a positive EMA recommendation. Once authorized, details regarding distribution, dosing schedules, and integration into national immunization programs will be communicated by public health authorities in each member state.
Stay informed about developments in preventive health and vaccine innovation by following updates from trusted sources such as the European Medicines Agency and national public health institutes. Share this information to help others stay protected against seasonal respiratory illnesses.